Form 4: PepGen CEO's Stock Options Repriced to $4.53

PepGen Inc.'s Board of Directors approved a repricing of President and CEO James G. McArthur's stock options, reducing the exercise price to $4.53, subject to retention.

Summary

• PepGen Inc.'s Board of Directors approved a repricing of outstanding stock options held by President and CEO James G. McArthur on November 4, 2025.
• The exercise price of eligible options, originally ranging from $8.96 to $16.62, was reduced to $4.53.
• All other terms of the options remain unchanged, except that the reduced exercise price is contingent upon the Reporting Person satisfying an applicable retention period; otherwise, the original exercise price will apply.
• The repricing affects options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan.
• The transactions are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934.
• The options generally vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder in 36 equal monthly installments, subject to continued service.

Sentiment

Score: 4

Explanation: The repricing of stock options is generally a negative signal as it implies significant past stock price underperformance. While it aims to re-incentivize management, it can lead to shareholder dilution and negative sentiment. The conditional nature of the repricing also adds a layer of uncertainty.

Positives

• The repricing provides a significantly lower exercise price for the CEO's stock options, potentially increasing their intrinsic value and re-incentivizing management.
• The Board's action aims to retain key executive talent by making existing equity awards more attractive, especially if the stock price has underperformed.

Negatives

• The repricing of stock options typically indicates a substantial decline in the company's stock price since the original grant dates, signaling past underperformance.
• Shareholders may view repricing negatively due to potential dilution from lower exercise prices and the perception of rewarding management despite stock price declines.
• The conditionality of the reduced exercise price on a retention period adds complexity and a potential hurdle for the CEO to fully realize the benefit.

Risks

• The implied risk of continued stock price underperformance, which necessitated the repricing.
• Risk of shareholder dissatisfaction and potential negative sentiment regarding executive compensation practices.
• The conditionality of the lower exercise price on a retention period introduces uncertainty regarding the ultimate benefit to the executive and the company's ability to retain the executive.

Future Outlook

The repricing aims to re-incentivize the President and CEO, James G. McArthur, by making his stock options more valuable, contingent on his continued service through specified vesting periods. This suggests a focus on long-term executive retention and alignment with future company performance.

Management Comments

• The Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan.
• The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply.

Industry Context

Stock option repricing is a practice often seen in growth-oriented sectors, such as biotechnology, particularly after periods of significant stock price decline. It is typically implemented to restore the incentive value of out-of-the-money options, thereby retaining and motivating key executives in a competitive talent market. This action by PepGen suggests a strategic move to re-align executive incentives with the company's current valuation and future growth prospects.

Comparison to Industry Standards

• Repricing of executive stock options is a practice observed across various industries, particularly in growth-oriented sectors like biotechnology, when a company's stock price has significantly underperformed its original grant prices.
• While it can be a tool for management retention and re-incentivization, it often signals past stock price weakness and can be viewed negatively by shareholders due to potential dilution and the perception of rewarding underperformance.
• No specific comparable companies or projects were mentioned in the filing to benchmark against, but the general industry trend for repricing is typically a response to market downturns or company-specific underperformance.

Corporate Governance

Related Party Transactions

• The repricing of stock options for James G. McArthur, the President and CEO, constitutes a related party transaction as it involves a change in compensation terms for a key executive.

Stakeholder Impact

• Shareholders: Potential negative impact due to implied past stock price underperformance and possible future dilution if the lower-priced options are exercised.
• Employees (specifically CEO): Positive impact through re-incentivization and increased potential value of equity awards, contingent on retention.

Next Steps

• James G. McArthur must satisfy applicable retention periods to qualify for the reduced exercise price on his stock options.
• Continued service by James G. McArthur is required for the stock options to vest according to their respective schedules (25% on first anniversary, then 36 equal monthly installments).

Key Dates

Recommendation

Repricing of executive stock options often signals significant past stock price underperformance, which is a negative indicator. However, it also aims to re-incentivize management, which could be a positive for future performance. A 'hold' recommendation is appropriate until further comprehensive financial results or strategic updates clarify the company's trajectory and the effectiveness of this incentive.

Keywords

PepGen, PEPG, stock options, repricing, executive compensation, Form 4, insider transaction, corporate governance, incentive plan